Latest early-stage breast cancer Stories
Cianna Medical, Inc.: Researchers from 12 sites report favorably low recurrence rates and minimal toxicities. CHICAGO (PRWEB) May 02, 2013 Strut-based
Cianna Medical, Inc: Recent studies conclude breast brachytherapy with the SAVI applicator appears to be a well-tolerated, effective treatment for early-stage breast cancer. New
Patients with early stage breast cancer who were treated with lumpectomy plus radiation may have a better chance of survival compared with those who underwent mastectomy.
According to the results of a new study published in the January 2012 issue of the Journal of the American College of Surgeons, many early-stage breast cancer survivors lacked knowledge about their disease and were not meaningfully involved in treatment discussions or asked their preferences regarding the approach to treatment.
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease.
Young women with early-stage breast cancer have similar survival rates with a lumpectomy and radiation treatment, known as breast-conservation therapy, as with mastectomy, a new study conducted at the University of Maryland has found.
A new study shows that removing lymph nodes due to the presence of occult, or microscopic, cancer cells found in the sentinel lymph node â€“ the one closest to the tumor -- has no impact on survival outcomes of women with early-stage breast cancer.
REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from ten separate studies at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2011 at McCormick Place in Chicago.
REDWOOD CITY, Calif. and ST. GALLEN, Switzerland, March 17, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from nine studies utilizing the Oncotype DXÂ® test in early-stage breast cancer patients at the 12th Annual St.
SAN ANTONIO, Dec. 13, 2010 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from seven new studies focusing on its multigene Oncotype DX(Â®) breast cancer test, which has helped guide treatment decisions in more than 175,000 breast cancer patients worldwide.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.